Background Steroid‐sparing strategies have been attempted in recent decades to avoid
morbidity from long‐term steroid intake among kidney transplant recipients. Previous …

Renal transplant recipients have increased mortality rates when compared with the general
population. The new immunosuppressive drugs have improved short-term patient survival …

This review aims to provide an update of the literature on the pharmacology and toxicology
of mycophenolate in solid organ transplant recipients. Mycophenolate is now the …

Abstract Context The European Association of Urology (EAU) panel on renal transplantation
(RT) has released an updated version of the RT guidelines. Objective To present the 2018 …

Background. Mycophenolate mofetil (MMF) has increasingly replaced azathioprine (AZA) as
the antimetabolite of choice in immunosuppressive protocols. Initial trials comparing MMF …

Background Modern immunosuppressive regimens after kidney transplantation usually use
a combination of two or three agents of different classes to prevent rejection and maintain …

Organ transplantation is a life-saving therapeutic intervention that contributes to a better
quality of life in patients with end-stage organ failure. Drastically improved outcome after …

Over the last decades, our understanding of adaptive immune responses to solid organ
transplantation increased considerably and allowed development of immunosuppressive …

The patent of mycophenolate mofetil (MMF) has expired, and for enteric‐coated
mycophenolate sodium (EC‐MPS), this will happen in 2017. In the twenty years these drugs …

Background. There have been striking changes during the last 10 years concerning the
choice of calcineurin inhibitor and antimetabolite agent prescribed after kidney …